Dr. Pouliot obtained doctorates in medicine (M.D.) and in Physiology-Endocrinology (Ph.D.) from Laval University. After completing a residency in Urology (F.R.C.S.C.), he did a post-doctoral fellowship in Urologic Oncology and molecular imaging at the University of California, Los Angeles (UCLA). Since 2010, he has practiced as a urologist-oncologist in the Quebec City University Hospital Center. He is also an assistant professor in Laval University’s Department of surgery. He oversees the CHU de Québec multidisciplinary clinic in castration-resistant prostate cancer. In 2014, he was the recipient of the Prostate Cancer Canada/Movember Rising Star Award. He is also the recipient of the FRQS Clinical Research Scholars Junior 1 and 2. His clinical and preclinical research interests include the detection and characterization of advanced prostate cancers using transcriptional amplification systems or positron emission tomography (PET) with tracers such as fluoro-deoxyglucose or PSMA ligands (PyL, MP-1404).

His research program has four aims: 1) To develop a dynamic imaging method of circulating tumor cells based on a transcriptional amplification system allowing the sensitive detection of a luminescent reporter gene under the control of prostate cancer specific promoters. This microscopy method will allow to predict the patient’s response to systemic treatments, by analysing the circulating tumor cell responses to treatment in ex vivo culture. 2) Use positron emission tomography imaging (PET/CT) as a quantitative method to assess metastasis individual response, in addition to global response to systemic treatment. 3) Develop a prostate cancer immunotherapy based on a transcriptional amplification system specific to prostate cancer. This vaccine vector will allow the introduction of recombinant genes in patient’s prostate cancer cells to induce an efficient immune response against cancer cells. 4) Characterize the androgen receptor (AR) activation in castration resistant prostate cancer patients. This project aims to determine which steroids activate the AR under chemical castration and to identify new AR interacting partners using proteomics.

L'Hôtel-Dieu de Québec
6, rue McMahon
0624
Québec, Québec
Canada G1R 2J6
65 entries « 2 of 7 »

Wong ECL, Breau RH, Mallick R, Wood L, Pouliot F, Basappa NS, Tanguay S, Soulieres D, So A, Heng D, Lavallee LT, Drachenberg D, Kapoor A

Renal cell carcinoma in the Canadian Indigenous population.

Journal Article

Curr Oncol, 26 (3), pp. e367-e371, 2019, ISSN: 1198-0052.

Abstract | Links:

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T, KEYNOTE-426 Investigators

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Journal Article

N Engl J Med, 380 (12), pp. 1116-1127, 2019, ISSN: 0028-4793.

Abstract | Links:

Goulet CR, Champagne A, Bernard G, Vandal D, Chabaud S, Pouliot F, Bolduc S

Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling.

Journal Article

BMC Cancer, 19 (1), pp. 137, 2019.

Abstract | Links:

Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P

Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.

Journal Article

Eur Urol Oncol, 2019, ISSN: 2588-9311.

Abstract | Links:

Jain P, Clermont PL, Desmeules F, Zoubeidi A, Neveu B, Pouliot F

Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells.

Journal Article

Int J Mol Sci, 20 (1), 2019.

Abstract | Links:

Breau RH, Cagiannos I, Knoll G, Morash C, Cnossen S, Lavallee LT, Mallick R, Finelli A, Jewett M, Leibovich BC, Cook J, LeBel L, Kapoor A, Pouliot F, Izawa J, Rendon R, Fergusson DA

Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol.

Journal Article

BMJ Open, 9 (1), pp. e025662, 2019.

Abstract | Links:

Rouleau M, Lemire F, Dery M, Theriault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guerette D, Pouliot F

Discordance between testosterone measurement methods in castrated prostate cancer patients.

Journal Article

Endocr Connect, 2019, ISSN: 2049-3614.

Abstract | Links:

Nguile-Makao M, Allard MA, Bairati I, Meyer F, Robitaille K, Fradet Y, Lacombe L, Pouliot F, Toren P, Duchesne T, Fradet V

Charlson Comorbidity Index as a Predictor of Cancer Mortality Beyond 10 Years after Radical Prostatectomy

Journal Article

Clin Oncol (Belmont), 4 , pp. 1638 (5 pages), 2019.

Ringuette-Goulet C, Bolduc S, Pouliot F

Modeling human bladder cancer.

Journal Article

World J Urol, 36 (11), pp. 1759-1766, 2018, ISSN: 0724-4983.

Abstract | Links:

Toren P, Hoffman A, Ding K, Joncas FH, Turcotte V, Caron P, Pouliot F, Fradet Y, Levesque E, Guillemette C, Klotz LH

Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial.

Journal Article

Clin Cancer Res, 24 (21), pp. 5305-5312, 2018, ISSN: 1078-0432.

Abstract | Links:

65 entries « 2 of 7 »
Signaler des ajouts ou des modifications

Active projects

  • (FRSQ 84874) Support statistique pour la recherche en Urologie-oncologie, Subvention, Fondation du CHU de Québec, from 2019-03-25 to 2020-03-24
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • National Program on Radioligand Therapy for Prostate Cancer, Subvention, Cancer de la prostate Canada, from 2018-01-01 to 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapie ciblée, Subvention, Fonds de recherche du Québec - Santé, ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer, from 2018-04-01 to 2021-03-31
  • Utilisation de l’imagerie moléculaire par microscopie à bioluminescence ou par tomographie par émission de positrons afin d’optimiser les stratégies thérapeutiques des patients atteints de cancers urologiques, Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, from 2019-07-01 to 2023-06-30

Recently finished projects

  • (FRSQ 78541)CUA‐CUOG Astellas Research Grant Program, Subvention, Canadian Urologic Oncology Group, from 2017-06-07 to 2018-06-06
  • (FRSQ 78573) Recherche sur la technique de microscopie bioluminescence pour cancers prostatiques, Subvention, Fondation du CHU de Québec, from 2017-07-10 to 2018-07-09
  • (FRSQ 82588) soutien du projet de recherche sur le cancer de la prostate - Urologie recherche - CHU, Subvention, Fondation du CHU de Québec, from 2018-09-13 to 2019-03-31
  • (FRSQ 82592)Soutien du projet de recherche pour le cancer de la prostate, Subvention, Fondation du CHU de Québec, from 2018-09-13 to 2019-03-31
  • Development of a urine-based prostate cancer cell bioluminescence imaging nanotechnology for single cell transcriptional characterization, Subvention, Société de recherche sur le cancer, Subvention de fonctionnement, from 2016-09-01 to 2018-08-31
  • Développement et utilisation de systèmes d’amplification transcriptionnelle multigéniques à des fins diagnostiques et thérapeutiques pour améliorer la prise en charge du cancer de la prostate., Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, from 2017-07-01 to 2019-06-30
Data provided by the Université Laval research projects registery